TABLE 5.

Associations between lifetime activity score, HRT use, aspirin/NSAID use, and body size with breast cancer risk in postmenopausal women

Lifetime activity score	Non-Hispanic white			Hispanic/American Indian
	0–4	5–8	9–12	0–4	5–8	9–12
	OR (95% CI)*	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)
Recent hormone exposure
Yes	1.00	0.97 (0.75, 1.25)	0.98 (0.74, 1.30)	1.00	1.00 (0.70, 1.45)	1.12 (0.69, 1.81)
No	0.87 (0.62, 1.22)	0.85 (0.62, 1.17)	0.49 (0.33, 0.73)	1.28 (0.86, 1.91)	1.11 (0.72, 1.71)	0.86 (048, 1.57)
p Interaction			0.01			0.47
No recent hormone exposure
Aspirin/NSAID use
Ever	1.00	0.67 (0.36, 1.25)	0.37 (0.19, 0.75)	1.00	1.20 (0.50, 2.91)	1.09 (0.38, 3.19)
Never	0.60 (0.34, 1.04)	0.73 (0.43, 1.23)	0.41 (0.23, 0.76)	1.69 (0.81, 3.54)	1.37 (0.63, 2.99)	0.95 (0.36, 2.49)
p Interaction			0.07			0.64
Referent year BMI (kg/m2)
<25	1.00	0.78 (0.40, 1.52)	0.59 (0.28, 1.22)	1.00	1.48 (0.54, 4.11)	0.26 (0.06, 1.14)
25–29.9	1.36 (0.70, 2.64)	1.50 (0.79, 2.85)	0.72 (0.34, 1.53)	0.53 (0.24, 1.17)	0.74 (0.32, 1.71)	0.63 (0.20, 2.05)
≥30	1.37 (0.69, 2.71)	1.45 (0.76, 2.76)	0.75 (0.35, 1.64)	1.00 (0.46, 2.17)	0.49 (0.21, 1.11)	0.61 (0.23, 1.64)
p Interaction			0.72			0.04
Weight gain between age 15 and referent year (kg)
≤10	1.00	0.84 (0.40, 1.78)	0.49 (0.20, 1.20)	1.00	1.89 (0.58, 6.18)	0.15 (0.03, 0.86)
10.1–20.0	0.63 (0.28, 1.41)	0.82 (0.38, 1.77)	0.56 (0.25, 1.27)	0.61 (0.23, 1.60)	0.76 (0.27, 2.14)	1.22 (0.28, 5.27)
>20.0	1.55 (0.78, 3.08)	1.21 (0.62, 2.36)	0.71 (0.33, 1.49)	0.92 (0.38, 2.22)	0.57 (0.23, 1.41)	0.69 (0.24, 2.02)
p Interaction			0.43			0.05

BMI = body mass index; CI = confidence interval; NSAID = nonsteroidal anti-inflammatory drug(s); OR = odds ratio.

^*ORs and 95% CIs adjusted for age, center, parity, BMI (except BMI models), and energy intake.